Promising drug results
An Alzheimer’s drug from the Japanese pharmaceutical firm Eisai has been shown to slow down patients’ decline in memory, thinking and function in the final stage of trials. The drug, called lecanemab, demonstrated promising results in a phase 3 trial and works by removing Alzheimer’s trademark amyloid protein from the brain. Early results indicated that…